natgillin/translations-raw huggingface dataset:
• Porcine circovirus type 2 (PCV2) infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).
• Okužbe s prašičjim cirkovirusom tipa 2 (PCV2) se kažejo s kliničnimi znaki, kot so zmanjšanje telesne mase ali zastoj rasti, povečane bezgavke, oteženo dihanje, driska, bleda koža in zlatenica (rumeno obarvanje kože).
This will help protect the pigs against porcine circovirus and Mycoplasma hyopneumoniae infections.
To bo prašičem pomagalo pri zaščiti pred okužbami s prašičjim cirkovirusom in bakterijo Mycoplasma hyopneumoniae.
The vaccine is given to pigs from three days of age as two injections into the neck muscle at least 18 days apart, or from three weeks of age as a single injection into the neck muscle.
Cepivo se daje prašičem od treh dni starosti naprej z dvakratnim injiciranjem v vratno mišico, in sicer v razmiku vsaj 18 dni, ali od treh tednov starosti naprej z enkratnim injiciranjem v vratno mišico.
The most common side effect (seen in more than 1 in 10 pigs) with Porcilis PCV M Hyo is a short-lived increase in body temperature of up to 2 °C on the day of vaccination.
Najpogostejši neželeni učinek cepiva Porcilis PCV M Hyo (ki so ga opazili pri več kot 1 prašiču od 10) je kratkotrajno zvišanje telesne temperature za do 2 °C na dan cepljenja.
Porcilis PCV M Hyo is an emulsion containing mineral oil.
Zdravilo Porcilis PCV M Hyo je emulzija, ki vsebuje mineralno olje.
When Porcilis PCV M Hyo is given to pigs the animals' immune system recognises the virus protein and bacteria as ‘foreign' and makes antibodies against them.
Ko prašiči prejmejo cepivo Porcilis PCV M Hyo, imunski sistem živali prepozna virusne beljakovine in bakterije kot „tujke“ ter začne proti njim tvoriti protitelesa.
The two-dose vaccination schedule is recommended when PCV2 and/or Mycoplasma hyopneumoniae infections occur early.
Shema cepljenja z dvema odmerkoma je priporočena, kadar se okužbi z virusom PCV2 in/ali bakterijo Mycoplasma hyopneumoniae pojavita zgodaj.
The effectiveness of Porcilis PCV M Hyo was investigated in 10 field studies involving pig farms where signs of PCV2 and/or Mycoplasma hyopneumoniae infections had been detected.
Učinkovitost cepiva Porcilis PCV M Hyo so proučevali v desetih terenskih študijah na prašičjih farmah, na katerih so zabeležili znake okužbe z virusom PCV2 in/ali bakterijo Mycoplasma hyopneumoniae.
• Infection with the bacterium Mycoplasma hyopneumoniae in pigs causes a disease of the airways called enzootic pneumonia.
• Okužba z bakterijo Mycoplasma hyopneumoniae pri prašičih povzroči bolezen dihalnih poti,
Other information about Porcilis PCV M Hyo
Druge informacije o zdravilu Porcilis PCV M Hyo
An overview of Porcilis PCV M Hyo and why it is authorised in the EU
Pregled zdravila Porcilis PCV M Hyo in zakaj je odobreno v EU
Porcilis PCV M Hyo received a marketing authorisation valid throughout the EU for Porcilis PCV M Hyo on 7 November 2014.
Zdravilo Porcilis PCV M Hyo je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 7. novembra 2014.
Porcilis PCV M Hyo (Porcine circovirus and Mycoplasma hyopneumoniae vaccine, inactivated)
Porcilis PCV M Hyo (cepivo proti prašičjemu cirkovirusu in bakteriji Mycoplasma hyopneumoniae, inaktivirano)
The field studies showed that both single and repeated vaccination with Porcilis PCV M Hyo reduced PCV2 levels in the blood and the severity of lung damage (lesions) caused by Mycoplasma hyopneumoniae as well as the loss of daily weight gain during the finishing period (the fattening period prior to slaughter).
Terenske študije so pokazale, da je cepljenje s cepivom Porcilis PCV M Hyo zmanjšalo ravni virusa PCV2 v krvi, resnost lezij v pljučih zaradi bakterije Mycoplasma hyopneumoniae in dnevno izgubo telesne mase v zaključnem obdobju (obdobju pitanja pred zakolom).
Porcilis PCV M Hyo is a vaccine.
Zdravilo Porcilis PCV M Hyo je cepivo.
Porcilis PCV M Hyo contains the adjuvants light mineral oil and aluminium hydroxide to enhance the immune response.
Zdravilo Porcilis PCV M Hyo vsebuje tudi adjuvansa, lahko mineralno olje in aluminijev hidroksid, ki povečata imunski odziv.
Why is Porcilis PCV M Hyo authorised in the EU?
Zakaj je bilo zdravilo Porcilis PCV M Hyo odobreno v EU?
What are the risks associated with Porcilis PCV M Hyo?
Kakšna tveganja so povezana z zdravilom Porcilis PCV M Hyo?
Porcilis PCV M Hyo is available as an injection and can only be obtained with a prescription.
Zdravilo Porcilis PCV M Hyo je na voljo v obliki injekcije, predpisovanje in izdaja zdravila je le na recept.
In each study around 300 suckling piglets were vaccinated once with Porcilis PCV M Hyo and a second similar-sized group of piglets received a dummy injection.
V vsaki študiji so približno 300 sesnih pujskov cepili s cepivom Porcilis PCV M Hyo, približno 300 sesnim pujskom pa so injicirali zdravilo brez učinkovine.
Porcilis PCV M Hyo contains porcine circovirus type 2 (PCV2) subunit antigen (a protein derived from part of the virus) and an inactivated (killed) strain of Mycoplasma hyopneumoniae bacteria.
Zdravilo Porcilis PCV M Hyo vsebuje podenoto antigena prašičjega cirkovirusa tipa 2 (PCV2) (beljakovine, pridobljene iz dela virusa) in inaktiviran (neživ) sev bakterije Mycoplasma hyopneumoniae.
What is Porcilis PCV M Hyo and what is it used for?
Kaj je zdravilo Porcilis PCV M Hyo in za kaj se uporablja?
What benefits of Porcilis PCV M Hyo have been shown in studies?
Kakšne koristi je zdravilo Porcilis PCV M Hyo izkazalo v študijah?
Laboratory studies in pigs showed that with two-dose vaccination the vaccine had its full effect against PCV2 by 18 days after first injection and against Mycoplasma hyopneumoniae by three weeks after the second injection, whilst with single-dose vaccination the vaccine had its full effect against PCV2 by two weeks and against Mycoplasma hyopneumoniae by four weeks.
Laboratorijske študije pri prašičih so pokazale, da je cepivo pri cepljenju z dvema odmerkoma svoj polni učinek proti virusu PCV2 doseglo v 18 dneh po prvi injekciji, proti bakteriji Mycoplasma hyopneumoniae pa v treh tednih po drugi injekciji.
Porcilis PCV M Hyo is a veterinary vaccine used to protect pigs against two separate infections, caused by porcine circovirus and Mycoplasma hyopneumoniae.
Zdravilo Porcilis PCV M Hyo je cepivo za uporabo v veterinarski medicini, ki se uporablja za zaščito prašičev pred dvema različnima okužbama, tj. prašičjim cirkovirusom ini bakterijo Mycoplasma hyopneumoniae.
With two-dose vaccination, protection against PCV2 starts at 18 days after the first injection and for Mycoplasma hyopneumoniae it starts 3 weeks after the second injection.
Pri cepljenju z dvema odmerkoma nastopi zaščita proti virusu PCV2 18 dni po prvem injiciranju, zaščita proti bakteriji Mycoplasma hyopneumoniae pa nastopi tretji teden po drugem injiciranju.
How is Porcilis PCV M Hyo used?
Kako se zdravilo Porcilis PCV M Hyo uporablja?
The withdrawal period for Porcilis PCV M Hyo is zero days.
Karenca za cepivo Porcilis PCV M Hyo je nič dni.
With single-dose vaccination, protection against PCV2 starts at two weeks after the injection and for Mycoplasma hyopneumoniae it starts four weeks after the injection.
Pri cepljenju z enkratnim odmerkom nastopi zaščita proti virusu PCV2 dva tedna po injiciranju, zaščita proti bakteriji Mycoplasma hyopneumoniae pa nastopi četrti teden po injiciranju.
For both vaccination schedules protection lasts for 22 weeks after (the last) injection for PCV2 and for 21 weeks after (the last) injection for Mycoplasma hyopneumoniae.
Pri obeh shemah cepljenja traja zaščita proti virusu PCV2 22 tednov od (zadnjega) injiciranja, zaščita proti bakteriji Mycoplasma hyopneumoniae pa traja 21 tednov od (zadnjega) injiciranja.
With both vaccination schedules protection lasted 22 weeks after (the last) injection for PCV2 and 21 weeks after (the last) injection for Mycoplasma hyopneumoniae.
Pri obeh shemah cepljenja je zaščita proti virusu PCV2 trajala 22 tednov od (zadnje) injekcije, proti bakteriji Mycoplasma hyopneumoniae pa 21 tednov od (zadnje) injekcije.
How does Porcilis PCV M Hyo work?
Kako zdravilo Porcilis PCV M Hyo deluje?
Date of first authorisation: 11/11/2016
Datum prve odobritve: 11. november 2016
- If you are pregnant or trying to become pregnant.
- če ste noseči ali želite zanositi.
Food delayed absorption by approximately 1 hour, and increased plasma exposure by 20 to 30%.
Hrana je upočasnila absorpcijo za približno 1 uro in povečala izpostavljenost v plazmi za 20 do 30 %.
- If you have heart failure which has recently become worse.
- če imate srčno popuščanje, ki se je pred kratkim poslabšalo.
Women that need treatment with ivabradine should stop breastfeeding, and choose for another way of feeding their child.
Ženske, ki potrebujejo zdravljenje z ivabradinom, naj prenehajo z dojenjem ter izberejo drug način hranjenja otroka.
- If you are a woman able to have children and not using reliable contraception.
- če ste ženska v rodni dobi in ne uporabljate zanesljive kontracepcije.
Name and address of the manufacturer responsible for batch release S.C. Zentiva S.A
Ime in naslov izdelovalca, odgovornega za sproščanje serij S.C. Zentiva S.A.
- Severe hypotension (< 90/50 mmHg).
- huda hipotenzija (< 90/50 mm Hg).
- If you are allergic to ivabradine or any of the other ingredients of this medicine (listed in section 6).
- če ste alergični na ivabradin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Do not use this medicine after the expiry date which is stated on the label and carton after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake “EXP”.
Tablets must be taken orally twice daily, i.e. once in the morning and once in the evening during meals (see section 5.2).
Tablete morajo bolniki jemati peroralno dvakrat na dan, to je eno zjutraj in eno zvečer med obrokom (glejte poglavje 5.2).
In this way Ivabradine Zentiva helps to control and reduce the number of angina attacks.
Na ta način Ivabradin Zentiva pripomore k nadzoru in zmanjševanju anginoznih napadov.
- If you suffer from very low blood pressure.
- če imate zelo nizek krvni tlak.
• Cisapride (against the gastro-oesophageal reflux).
• cisaprid (proti gastroezofagealnemu refluksu).
The total clearance is about 400 mL/min and the renal clearance is about 70 mL/min.
Skupni očistek znaša približno 400 ml/min in ledvični približno 70 ml/min.
- If you are suffering from cardiogenic shock (a heart condition treated in hospital).
- če imate kardiogeni šok (bolezen srca, ki zahteva zdravljenje v bolnišnici).
They generally occur within the first two months of treatment after which they may occur repeatedly and resolve during or after treatment.
Navadno se pojavijo v prvih dveh mesecih zdravljenja, nato se lahko občasno ponavljajo ter izginejo med ali po zdravljenju.
Under physiological conditions, ivabradine is rapidly released from tablets and is highly water-soluble (> 10 mg/mL).
V fizioloških pogojih se ivabradin hitro sprošča iz tablet in je zelo topen v vodi (> 10 mg/ml).
032266 Bucharest Romania
032266 Bucharest Romunija
If you forget to take a dose of Ivabradine Zentiva, take the next dose at the usual time.
Če ste pozabili vzeti odmerek zdravila Ivabradin Zentiva, vzemite naslednji odmerek ob običajnem času.
- If you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that your heart is slowing down too much).
- če opažate simptome, kot so utrujenost, vrtoglavost ali zasoplost (to bi lahko pomenilo, da se vaše srce preveč upočasnjuje).
- If you have had a recent stroke (cerebral attack).
- če ste nedavno imeli možgansko kap (možganski napad).
However, in postmarketing experience, cases of impaired driving ability due to visual symptoms have been reported.
V obdobju trženja zdravila pa so poročali o primerih zmanjšane sposobnosti vožnje zaradi simptomov motenj vida.
The following adverse reactions have been reported during clinical trials and are ranked using the following frequency: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
V kliničnih študijah so poročali o naslednjih neželenih učinkih, ki so razvrščeni po naslednji pogostnosti: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000); neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
- Sino-atrial block.
- sinoatrijski blok.
- If you suffer from unstable angina (a severe form in which chest pain occurs very frequently and with or without exertion).
- če imate nestabilno angino pektoris (hudo obliko, pri kateri se bolečine v prsih pojavljajo zelo pogosto, med naporom ali brez njega).
If you think that the effect of Ivabradine Zentiva is too strong or too weak, talk to your doctor or pharmacist.
Če menite, da je učinek zdravila Ivabradin Zentiva premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
Ivabradine Zentiva is not intended for use in children and adolescents younger than 18 years.
Otroci Zdravilo Ivabradin Zentiva ni namenjen za uporabo pri otrocih in mladostnikih, mlajših od 18 let.
The calendar printed on the blister containing the tablets should help you remember when you last took a tablet of Ivabradine Zentiva.
Koledar, ki je natisnjen na pretisnem omotu s tabletami, vam pomaga, da si zapomnite, kdaj ste nazadnje vzeli tableto zdravila Ivabradin Zentiva.
- Rifampicin (an antibiotic).
- rifampicin (antibiotik).
- Cardiogenic shock.
- kardiogeni šok.
No data are available in patients with creatinine clearance below 15 mL/min.
Za bolnike z očistkom kreatinina pod 15 ml/min ni podatkov.
Hazard Ratio [95% CI]
razmerje tveganja [95% interval zaupanja]
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
• Anti-malarial medicines (such as mefloquine or halofantrine).
• zdravila proti malariji (na primer meflokin ali halofantrin).
Atrial fibrillation - cardiac arrhythmias
Atrijska fibrilacija - srčne aritmije
Combination with calcium channel blockers
Kombinacija z zaviralci kalcijevih kanalčkov
• Bepridil (to treat angina pectoris).
• bepridil (proti angini pektoris).
- If you suffer from symptoms of atrial fibrillation (pulse rate at rest unusually high (over 110 beats per minute) or irregular, without any apparent reason, making it difficult to measure).
- če imate simptome atrijske fibrilacije (nenavadno visok srčni utrip v mirovanju (nad 110utripov na minuto) ali brez posebnega vzroka nereden srčni utrip, ki ga je težko izmeriti).
If you are pregnant and have taken Ivabradine Zentiva, talk to your doctor.
Če ste noseči in ste jemali zdravilo Ivabradin Zentiva, se posvetujte z zdravnikom.
- If your resting heart rate before treatment is too slow (below 70 beats per minute).
- če je vaša srčna frekvenca med mirovanjem pred zdravljenjem prepočasna (manj kot 70 utripov na minuto).
Pharmacotherapeutic group: Cardiac therapy, other cardiac preparations; ATC code: C01EB17.
Farmakoterapevtska skupina: zdravila za bolezni srca, druga zdravila za bolezni srca; oznaka ATC: C01EB17.
- If you suffer from uncontrolled blood pressure, especially after a change in your antihypertensive treatment.
- če imate nenadzorovan krvni tlak, še posebno po zamenjavi zdravljenja zvišanega krvnega tlaka.
The European Medicines Agency has waived the obligation to submit the results of studies with ivabradine in all subsets of the paediatric population for the treatment of angina pectoris.
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Ivabradin Zentiva za vse podskupine pediatrične populacije za zdravljenje angine pektoris.
The antianginal and anti-ischaemic efficacy of ivabradine was preserved in diabetic patients (n = 457) with a similar safety profile as compared to the overall population.
Antianginozni in antiishemični učinek ivabradina se je ohranjal pri bolnikih s sladkorno boleznijo (n = 457) s podobnim profilom varnosti kot pri celotni populaciji.
The results on the primary endpoint are mainly driven by the heart failure endpoints, hospitalisation for worsening heart failure (absolute risk reduced by 4.7%) and deaths from heart failure (absolute risk reduced by 1.1%).
Rezultat končnega izida je izmerjen predvsem na podlagi izidov srčnega popuščanja, hospitalizacij zaradi poslabšanj srčnega popuščanja (absolutno zmanjšanje tveganja za 4,7 %) in umrljivosti zaradi srčnega popuščanja (absolutno zmanjšanje tveganja za 1,1 %).
Ivabradine is eliminated with a main half-life of 2 hours (70 - 75% of the AUC) in plasma and an effective half-life of 11 hours.
Ivabradin se izloča z glavno razpolovno dobo 2 uri (70 do 75 % površine pod krivuljo (AUC)) v plazmi in efektivno razpolovno dobo 11 ur.
Tablets are available in packs of 14, 28, 56, 84, 98, 100, 112 film-coated tablets.
Tablete so na voljo v pakiranjih, ki vsebujejo 14, 28, 56, 84, 98, 100, 112 filmsko obloženih tablet.
The safety and efficacy of ivabradine for the treatment of chronic heart failure in children aged below 18 years have not been established.
Varnost in učinkovitost ivabradina pri zdravljenju kroničnega srčnega popuščanja pri otrocih, mlajših od 18 let, nista bili dokazani.
Crospovidone Magnesium stearate
Jedro: manitol krospovidon magnezijev stearat
mefloquine, halofantrine, pentamidine, cisapride, intravenous erythromycin).
meflokin, halofantrin, pentamidin, cisaprid, eritromicin intravensko).
- Pregnancy, lactation and women of child-bearing potential not using appropriate contraceptive measures (see section 4.6).
- nosečnost, dojenje in ženske v rodni dobi, ki ne uporabljajo zanesljivih kontracepcijskih metod (glejte poglavje 4.6).
The European Medicines Agency has waived the obligation to submit the results of studies with ivabradine in children aged 0 to less than 6 months for the treatment of chronic heart failure.
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Ivabradin Zentiva za otroke od 0 do manj kot 6 mesecev starosti za zdravljenje kroničnega srčnega popuščanja.
Patients received standard care including beta-blockers (89%), ACE inhibitors and/or angiotensin II antagonists (91%), diuretics (83%), and anti-aldosterone agents (60%).
Bolniki so prejemali standardno zdravljenje, ki je vključevalo antagoniste adrenergičnih receptorjev beta (89 %), zaviralce ACE in/ali antagoniste angiotenzina II (91 %), diuretike (83 %) in antagoniste aldosterona (60 %).
- If you suffer from severe heart failure or heart failure with abnormality of ECG called “bundle branch block”.
- če imate hudo srčno popuščanje ali srčno popuščanje z nepravilnostjo EKG, ki se imenuje 'kračni blok'.
Ivabradine Zentiva mainly works by reducing the heart rate by a few beats per minute.
Ivabradin Zentiva deluje predvsem tako, da znižuje srčno frekvenco za nekaj utripov na minuto.
OPA/Alu/PVC-Alu blisters, paper carton.
OPA/Alu/PVC-Alu pretisni omoti, kartonska škatla.
- If your heartbeat is exclusively imposed by your pacemaker.
- če vam srčni utrip narekuje izključno vaš srčni spodbujevalnik.
Very common Luminous phenomena (phosphenes) Common
Očesne bolezni zelo pogosti pojavi svetlikanja (fosfeni)
14 film-coated tablets 28 film-coated tablets 56 film-coated tablets 84 film-coated tablets 98 film-coated tablets 100 film-coated tablets 112 film-coated tablets
14 filmsko obloženih tablet 28 filmsko obloženih tablet 56 filmsko obloženih tablet 84 filmsko obloženih tablet 98 filmsko obloženih tablet 100 filmsko obloženih tablet 112 filmsko obloženih tablet
Ivabradine is not effective in the treatment or prevention of cardiac arrhythmias and likely loses its efficacy when a tachyarrhythmia occurs (e.g. ventricular or supraventricular tachycardia).
Ivabradin ni učinkovit pri zdravljenju ali preprečevanju srčnih aritmij in verjetno izgubi učinkovitost ob pojavu tahiartimij (na primer ventrikularne ali supraventrikularne tahikardije).
Symptoms Overdose may lead to severe and prolonged bradycardia (see section 4.8).
Simptomi Preveliko odmerjanje lahko privede do hude in podaljšane bradikardije (glejte poglavje 4.8).
- Barbiturates (for difficult sleeping or epilepsy).
- barbiturate (proti nespečnosti ali epilepsiji).
- In patients with left ventricular dysfunction (left ventricular ejection fraction (LVEF) between 30 and 45%), ivabradine did not have any deleterious influence on LVEF.
- pri bolnikih z disfunkcijo levega prekata (iztisnim deležem levega prekata med 30 in 45 %) ivabradin ni imel nobenih škodljivih učinkov na iztisni delež levega prekata.
• Pentamidine (an antiparasitic medicine).
• pentamidin (zdravilo proti parazitom).
Ivabradine has been studied in clinical trials involving nearly 45,000 participants.
Povzetek varnostnega profila Ivabradin so proučevali v kliničnih študijah, ki so vključile skoraj 45.000 bolnikov.
- Unstable or acute heart failure.
- nestabilno ali akutno srčno popuščanje.
- If you suffer from a heart rhythm disorder.
- če imate motnje srčnega ritma.
If any of the above applies to you, talk straight away to your doctor before or while taking Ivabradine Zentiva.
Če karkoli od naštetega velja za vas, se takoj pogovorite z zdravnikom pred jemanjem zdravila Ivabradin Zentiva ali med njim.
Fertility Studies in rats have shown no effect on fertility in males and females (see section 5.3).
Plodnost Študije na podganah niso pokazale učinka na plodnost pri samcih in samicah (glejte poglavje 5.3).
• Intravenous erythromycin (an antibiotic).
• eritromicin v žilo (antibiotik).
Lack of benefit on clinical outcomes in patients with symptomatic chronic stable angina pectoris
Pomanjkanje koristi na klinične izide pri bolnikih s simptomatsko kronično angino pektoris
Concomitant use with precautions
Sočasno jemanje ob previdnostnih ukrepih
Contents of the pack and other information What Ivabradine Zentiva contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje Ivabradin Zentiva
- Resting heart rate below 70 beats per minute prior to treatment.
- srčna frekvenca med mirovanjem pod 70 utripov na minuto pred zdravljenjem.
- If you suffer from chronic eye retinal disease.
- če imate kronično bolezen mrežnice očesa.
However, in the absence of extensive data, non-urgent DC-cardioversion should be considered 24 hours after the last dose of ivabradine.
Toda ker ni obsežnejših podatkov, razmislite o neurgentni kardioverziji z enosmernim tokom v 24 urah po zadnjem odmerku ivabradina.
Pharmacokinetic/pharmacodynamic (PK/PD) relationship PK/PD relationship analysis has shown that heart rate decreases almost linearly with increasing ivabradine and S 18982 plasma concentrations for doses of up to 15 - 20 mg twice daily.
Farmakokinetično/farmakodinamično (PK/PD) razmerje Analiza razmerja med farmakokinetiko in farmakodinamiko je pokazala, da se srčna frekvenca znižuje skoraj linearno s povečevanjem koncentracije ivabradina in S 18982 v plazmi ob odmerkih do 15 do 20 mg dvakrat na dan.
The most common symptoms of heart failure are breathlessness, fatigue, tiredness and ankle swelling.
Najpogostejši simptomi srčnega popuščanja vključujejo zasoplost, slabotnost, utrujenost in otekanje gležnjev.
Ivabradine Zentiva may cause temporary luminous visual phenomena (a temporary brightness in the field of vision, see “Possible side effects”).
Zdravilo Ivabradin Zentiva lahko povzroča začasne vidne pojave svetlikanja (prehodno povečanje svetlosti v vidnem polju, glejte “Možni neželeni učinki”).
- Unstable angina.
- nestabilna angina pektoris.
These data are consistent with the pharmacological effect of ivabradine related to its interaction with hyperpolarisationactivated Ih currents in the retina, which share extensive homology with the cardiac pacemaker If current.
Ti podatki so skladni s farmakološkim učinkom ivabradina, povezanim z njegovim medsebojnim delovanjem z mrežničnimi hiperpolarizacijsko sproženimi tokovi Ih, ki si delijo obširno homologijo s srčnim frekvenčno urejevalnim tokom If.